Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADX-850 in Hypertension
NCT06205628Phase 1Active, not recruiting
- Sponsor
- ADARx Pharmaceuticals
- Start
- Mar 2024
- Primary completion
- Oct 2026
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised trial in hypertension (HTN) comparing ADX-850 with Placebo (2 arms). Primary endpoint: Safety of ADX-850 in Participants with Hypertension at 365 days. Started Mar 2024; status: active, not recruiting.
02
Drugs
ADX-850
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT06205628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06205628.